Live Analysis:
Edwards Lifesciences Corporation (EW) is currently priced at $81.75, showing a decrease of $1.71 (-2.04%) from the previous close of $83.46. The trading volume stands at $1 million, 20.88% above the average.
Earnings Overview:
In the latest quarterly earnings report released on Tuesday, April 21st, EW reported earnings per share (EPS) of 66 cents, slightly below the consensus estimate of 72 cents.
Grades:
Barclays maintained EW's rating as "Overweight," with the stock price at $84.15. The latest action is to "hold."
Cash Flow:
EW generated a free cash flow of $353.5 million, with a net cash increase of $244.7 million. Operating cash flow was $450.9 million, while common stock repurchased was $-40.60 million.
Income Statement:
EW reported revenue of $1.65 billion, gross profit of $1.29 billion, and net income of $380.7 million. The company's EPS and diluted EPS both stood at 66 cents.
Ratios:
Key ratios include a gross profit margin of 78.21%, operating profit margin of 31.22%, and a price-to-sales ratio of 28.13.
Balance Sheet:
EW holds $2.94 billion in cash and cash equivalents, with total assets amounting to $13.70 billion and total liabilities at $3.36 billion.
This comprehensive analysis reflects the current financial standing and performance of Edwards Lifesciences Corporation, indicating a challenging market environment for the company.
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.